一次情報の記録
FDA cleared the IND for MGX-001, enabling initiation of the Phase 1/2 INTEGR8 trial. The company plans to start the trial in H1 2027 and report initial clinical data (safety, tolerability, FVIII activity) in H2 2027.
EX-99.1 2 mgx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results FDA clearance enables initiation of a first-in-human Phase 1/2 trial of MGX-001 in patients with hemophilia A MGX-001 is designed to deliver durable, endogenous Factor VIII (FVIII) activity from a one-time treatment for adults and children Company plans to initiate the INTEGR8 clinical trial in the first half of 2027 and provide initial clinical data in the second half of 2027 $101.7 million in cash, cash equivalents, and available-for-sale marketable securities as of September 30, 2026, with runway anticipated to support operations into 2028 EMERYVILLE, Calif., November 10, 2026 (GLOBE